poisar

Stocks · News reference

Oragenics, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2026

Fiscal.ai

Oragenics, Inc. released its financial results for the third quarter and nine months ended September 30, 2026, which were followed by a significant decline in the company's share price.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — ORAGENICS INC (OGEN)

    Filed: 2026-09-16 AccNo: 0001493152-26-042843 Size: 7 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

  2. BenzingaBenzinga Newsdesk

    Oragenics Advances Phase IIa Trial With 9 Participants Dosed; Recieved NYSE American Non Compliance Letter, Has 45 Days From Receipt Of The Deficiency Letter Within Which To Submit A Plan To Regain Compliance With The Continued Listing Standards

    Oragenics, Inc. (NYSE:OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical